Investigation announced for Investors in shares of Biomea Fusion, Inc. (NASDAQ: BMEA) over possible Violations of Securities Laws

An investigation was announced for investors of Biomea Fusion, Inc. (NASDAQ: BMEA) shares over potential securities laws violations by Biomea Fusion, Inc. in connection with certain financial statements.

Investors who purchased shares of Biomea Fusion, Inc. (NASDAQ: BMEA), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Biomea Fusion, Inc. (NASDAQ: BMEA) concerning whether a series of statements by Biomea Fusion, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Redwood City, CA based Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases.

On June 6, 2024, Biomea issued a press release "announc[ing] that the Company has received notice from the U.S. Food and Drug Administration (FDA) that a full clinical hold has been placed on Biomea's ongoing Phase I/II clinical trials of the Company's investigational covalent menin inhibitor BMF-219 in type 2 and type 1 diabetes (COVALENT-111 and COVALENT-112), respectively." The press release stated that "[t]he FDA cited deficiencies based on the level of possible drug-induced hepatotoxicity observed in the completed Dose Escalation Phase of COVALENT-111."

Shares of Biomea Fusion, Inc. (NASDAQ: BMEA) declined from $22.74 per share on December 04, 2023, to as low as $4.15 per share on July 05, 2024.

Those who purchased shares of Biomea Fusion, Inc. (NASDAQ: BMEA) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.